Hepatitis C

Employees with hepatitis C (HCV) who underwent existing treatments had more absences and higher indirect costs than HCVinfected employees who did not undergo treatment.

HCV Screening Practices and Prevalence in an MCO, 2000-2007

ByDouglas W. Roblin, PhD,Bryce D. Smith, PhD,Cindy M. Weinbaum, MD, MPH,Miriam E. Sabin, PhD

August 5th 2011

HCV screening and prevalence estimates, unadjusted and adjusted for HCV risk factors, are examined in this 8-year observational study of a managed care organization.

Case 2: Emerging Therapeutic Options in Hepatitis C Virus Infection (CE)

Byby Fred Poordad, MD,Vandana Khungar, MD, MSc

April 26th 2011

Hepatitis C

Latest News

Recap: The 53rd American Society of Hematology Annual Meeting and Exposition

Hepatitis C Birth Cohort Screening is Cost-Effective

Absenteeism and Productivity Among Employees Being Treated for Hepatitis C

HCV Screening Practices and Prevalence in an MCO, 2000-2007

Case 2: Emerging Therapeutic Options in Hepatitis C Virus Infection (CE)

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Monoclonal Antibodies Had Varying Efficacy in Treating MG